REALITY Trial Investigators’ Expectations May Have Been Unrealistic – JAMA
This article was originally published in The Gray Sheet
Executive Summary
Investigators in the Johnson & Johnson-sponsored REALITY drug-eluting stent trial should not have expected large differences in outcomes between J&J's Cypher and Boston Scientific's Taxus, according to an editorial in the Feb. 22 issue of the Journal of the American Medical Association
You may also be interested in...
Cypher Edges Out Taxus In A Meta-Analysis Of Six Head-To-Head Trials
A meta-analysis of six drug-eluting stent trials suggests that sirolimus-elutings stents are associated with a lower risk of restenosis and target vessel revascularization than paclitaxel-eluting stents
Boston Scientific, J&J Dwell In Separate REALITY; Data Swamps ACC
Johnson & Johnson is emphasizing Cypher's low thrombosis rates after the sirolimus-eluting stent failed to show clinical superiority over Boston Scientific's Taxus
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.